pyrotinib + pemetrexed + carboplatin

The combination of pyrotinib, pemetrexed, and carboplatin appears to be a treatment regimen used primarily for non-small cell lung cancer (NSCLC), particularly for HER2-mutant NSCLC. This combination represents a targeted therapy approach combined with chemotherapy agents. ## Drug Information Pyrotinib is an irreversible pan-ErbB receptor tyrosine kinase inhibitor (TKI) that targets HER2 mutations. It has shown efficacy in treating HER2-positive cancers, including breast cancer and lung cancer with HER2 mutations. Pemetrexed is a folate analog that disrupts folate-dependent metabolic processes essential for cell replication. It's commonly used in combination with platinum-based agents like carboplatin for treating non-squamous NSCLC and malignant pleural mesothelioma. Carboplatin is a platinum-based chemotherapy drug that destroys quickly dividing cells, such as cancer cells. It's often paired with pemetrexed for treating non-small cell lung cancer. ## Clinical Use The combination therapy appears to be particularly promising for HER2-mutant non-small cell lung cancer. According to the search results, pyrotinib-based combination therapy with chemotherapy has demonstrated significant survival benefits compared to monotherapy approaches. In HER2-mutant NSCLC, the combination of pyrotinib with chemotherapy as first-line treatment achieved superior outcomes with a median progression-free survival (PFS) of 11.3 months and median overall survival (OS) of 21.0 months. This compares favorably to pyrotinib monotherapy, which showed a median PFS of 7.3 months and median OS of 14.3 months in the CTONG1702 study. ## Safety Profile The safety profile of this combination appears to be manageable. The pyrotinib-based regimen shows advantages in terms of safety and tolerability compared to some other treatments, particularly with a lower incidence of interstitial lung disease. For the pemetrexed and carboplatin components, common side effects include hematologic toxicities (particularly in elderly patients), which can be managed with dose adjustments. Supportive care typically includes folic acid supplementation and vitamin B12 injections to reduce side effects of pemetrexed. This combination represents an emerging approach in precision oncology, targeting specific molecular alterations (HER2 mutations) while also providing the broader cytotoxic effects of traditional chemotherapy agents.

Other names

Pyrotinib plus pemetrexed and carboplatinPyrotinib combined with pemetrexed plus carboplatin